Evonik Vland Biotech Launches Joint Venture to Enhance Animal Gut Health Solutions

Evonik Vland Biotech Launches Joint Venture to Enhance Animal Gut Health Solutions

(IN BRIEF) The joint venture, Evonik Vland Biotech, established by Evonik China and Shandong Vland Biotech, officially commenced operations in Binzhou, China, aiming to bolster the market presence of probiotics for livestock gut health in the Greater China region while fostering new product development. With a decade-long partnership between Evonik and Vland, the venture marks a significant step in Evonik’s strategy to provide biosolutions for the feed industry, aligning with its focus on innovative solutions at the nexus of biotechnology and data science. Positioned at Vland Biotech Park in Qingdao, the joint venture emphasizes customer-centric innovation, leveraging the expertise and reputation of both parent companies to deliver effective solutions worldwide.

(PRESS RELEASE) ESSEN, 15-Mar-2024 — /EuropaWire/ — The newly founded joint venture Evonik Vland Biotech, based in Binzhou, China, commenced operations on January 1, 2024. The two parent companies, Evonik China and Shandong Vland Biotech, want to jointly expand the market presence of their products, such as probiotics for the gut health of livestock in the Greater China region, and develop new products and solutions. The joint venture was officially opened in Qingdao on March 14.

The partnership with Vland is an essential part of Evonik’s strategy to provide the feed industry with biosolutions such as probiotics for animal gut health. “Vland and Evonik have been partnering for nearly 10 years. Through this relationship, we have created a strong foundation on which we can build”, said Johann-Caspar Gammelin, head of Evonik’s Nutrition & Care division, which includes the Animal Nutrition business.

Evonik’s biotech platform focuses on the development of biosolutions that enable a healthy life for all. This includes innovations at the interface between chemistry, biotechnology, pharmacology and data science, with which the company is opening up new horizons. One example of this is skin applications, which can complement the current activities in Evonik’s Care Solutions portfolio.

“Over the past decade, Vland and Evonik have been continuously broadened the scope of our cooperation and deepened our partnership,” said Arron Chen, Chairman and President of the Vland Group. “With the joint venture now fully operational, we are poised to capitalize on our expertise on the animal gut health and deliver effective and efficient products and solutions for our customers in China and worldwide.”

The joint venture is based at the Vland Biotech Park in Qingdao and uses Vland’s production facilities in Huimin. It positions itself as an innovative solution provider with a focus on customer proximity, quality and speed.

“Based on the strong innovation capabilities, application technology know-how and excellent reputation of both parent companies, Evonik Vland Biotech will bring innovative products and solutions to the market, always focusing on the value proposition for our customers,” said Dr. Xu Wang, General Manager of the joint venture.

Under the agreement with Vland, Evonik will also distribute the joint venture’s portfolio outside the Greater China region. The joint venture thus complements Evonik’s gut health portfolio with new components for formulated products and enables new solutions for gut health.

Gut health solutions form the core of the specialty business of Evonik’s Animal Nutrition business line. Probiotics such as Ecobiol®, Fecinor®, GutPlus® and GutCare® are currently the main products in the gut health portfolio. Probiotics consist of live microorganisms that are added to animal feed to maintain or restore the microbial balance in the gut, thereby increasing the animal’s resilience.

Evonik China Co., Ltd. and Shandong Vland Biotech Co., Ltd. announced their intention to establish a joint venture in October 2023. Evonik is the majority shareholder of Evonik Vland Biotech (Shandong) Co., Ltd. with 55 percent of the shares.

COMPANY INFORMATION

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.ABOUT NUTRITION & CARE

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.

DISCLAIMER

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Media Contacts:

Yama Olumi
Head of Market Communications
Animal Nutrition
Phone: +49 6181 59 12437
yama.olumi@evonik.com

Dr. Jürgen Krauter
Head of Market Communications
Evonik
Phone: +49 6181 59-6847
juergen.krauter@evonik.com

SOURCE: EVONIK